#United States #New York #Pomerantz Law Firm #Caribou Biosciences #CRBU

Investor Alert: Class Action Lawsuit Against Caribou Biosciences

The Pomerantz Law Firm has recently informed investors of a significant development regarding Caribou Biosciences, Inc. If you are one of the investors who sustained losses from your holdings in Caribou, you may be interested in this legal action. A class action lawsuit has been filed against the company, along with several of its top officials, in the United States District Court for the Northern District of California. This lawsuit is notably focused on the events occurring between July 14, 2023, and July 16, 2024, which forms the Class Period as defined by the complaint.

Legal Background and Allegations

The core issue of the lawsuit revolves around allegations that Caribou and its defendants made false and misleading statements regarding the company's operations and its flagship product, CB-010, an allogeneic anti-CD19 CAR-T cell therapy. Investors are claiming that they were misled about the efficacy, safety, and commercial viability of the product, ultimately affecting the value of their investments. Particularly, the complaint suggests that Caribou did not adequately disclose issues regarding the safety and effectiveness of CB-010 in comparison to other established treatments in the market.

According to the allegations, the plaintiffs argue that the defendants had overstated the results and durability of CB-010 and misrepresented the financial standing of Caribou, leading to a false sense of security among investors. Such actions are seen as violations of the federal securities laws under the Securities Exchange Act of 1934.

The lawsuit not only targets the company's misleading statements but also highlights significant risks that Caribou faced in terms of operational funding. Investors were not informed adequately about cash flow issues that could hinder business sustainability and ongoing projects, like those involving the allogeneic CAR-NK platform.

Recent Developments and Impacts

The situation took a pivotal turn on June 2, 2024, when Caribou released updated clinical trial data that purportedly demonstrated the potential of CB-010. However, contrary to the optimistic presentation, analysts from Evercore downgraded the firm’s stock, expressing doubts about its competitive viability compared to existing CAR-T therapies. Following that announcement, Caribou’s shares experienced a significant decline, dropping over 25% shortly after the data was made public.

Additionally, on July 16, 2024, Caribou announced the discontinuation of several of its preclinical research initiatives, as well as staff layoffs, which further raised concerns about the company's financial health and operational longevity. This prompted another decline in the stock price, further eroding confidence among investors.

Invitation to Join the Class Action

The Pomerantz Law Firm is reaching out to all individual and institutional investors who purchased Caribou biosciences' securities during the Class Period. If you are interested in taking part in this class action lawsuit, you must act swiftly as the deadline for appointing a Lead Plaintiff is February 24, 2025. Affected parties are encouraged to contact the firm directly for inquiry and participation, and access to the complaint can be found on their official website.

This legal action underscores the continuing scrutiny of biopharmaceutical companies and highlights the importance of transparency in corporate communications. Investors, especially those impacted by this situation, should remain informed of their rights and the steps necessary to potentially recover losses sustained during this tumultuous time.

For further discussion about this case, contact Danielle Peyton at Pomerantz LLP via email or by telephone. Additional details can also be found on their website dedicated to this kind of litigation. The firm has a longstanding reputation in securities class action cases and aims to support victims of corporate misdeeds diligently.

• ---